NASDAQ:CTMX - CytomX Therapeutics Stock Price, Price Target & More

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics Inc (NASDAQ:CTMX) announced its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.17. The biotechnology company earned $14.18 million during the quarter, compared to analysts' expectations of $19.77 million. CytomX Therapeutics had a negative net margin of 67.88% and a negative return on equity of 92.68%. View CytomX Therapeutics' Earnings History.

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for CytomX Therapeutics.

10 analysts have issued 12 month price objectives for CytomX Therapeutics' stock. Their predictions range from $37.00 to $44.00. On average, they expect CytomX Therapeutics' stock price to reach $39.8571 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price. View Analyst Ratings for CytomX Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to CytomX Therapeutics include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Akcea Therapeutics (AKCA) and Portola Pharmaceuticals (PTLA).

News headlines about CTMX stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.86 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

CytomX Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Foundry Partners LLC (0.10%), Bank of Montreal Can (0.09%), Essex Investment Management Co. LLC (0.06%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

CTMX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Foundry Partners LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.

CTMX stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for CytomX Therapeutics.

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTMX stock can currently be purchased for approximately $25.47.

CytomX Therapeutics has a market capitalization of $950.56 million and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]